Uticaj tocilizumaba na tok i ishod lečenja pacijenata sa COVID-19 pneumonijom - iskustvo bolnice sekundarnog nivoa

Key Points

• To assess the impact of tocilizumab on the treatment outcomes of patients with COVID-19 pneumonia.
• Analyzed treatment outcomes of patients receiving tocilizumab for COVID-19 pneumonia
• Evaluated clinical parameters and recovery rates
• Data collected from a secondary hospital setting
• Improvement in clinical outcomes observed in patients receiving tocilizumab
• Significant reduction in hospitalization duration noted
• Positive response rates to treatment were evident across different patient profiles